Gregory Lucier Purchases 10,000 Shares of Avantor (NYSE:AVTR) Stock

Avantor, Inc. (NYSE:AVTR) Director Gregory Lucier purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The stock was purchased at an average price of $8.32 per share, with a total value of $83,200.00. Following the completion of the purchase, the director directly owned 60,000 shares of the company’s stock, valued at approximately $499,200. This represents a 20.00% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Avantor Trading Up 2.4%

Shares of NYSE AVTR opened at $8.17 on Wednesday. The company has a quick ratio of 1.17, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The stock’s 50 day moving average price is $8.04 and its two-hundred day moving average price is $10.17. Avantor, Inc. has a 52-week low of $7.26 and a 52-week high of $15.93. The stock has a market capitalization of $5.57 billion, a P/E ratio of -10.08, a PEG ratio of 4.65 and a beta of 0.94.

Avantor (NYSE:AVTR) last issued its earnings results on Wednesday, April 29th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.16 by $0.01. The company had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.54 billion. Avantor had a positive return on equity of 9.95% and a negative net margin of 8.42%.The business’s revenue was up .0% on a year-over-year basis. During the same quarter last year, the firm earned $0.23 EPS. On average, analysts anticipate that Avantor, Inc. will post 0.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Avantor

Several institutional investors have recently modified their holdings of AVTR. EverSource Wealth Advisors LLC increased its holdings in shares of Avantor by 119.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,187 shares of the company’s stock worth $29,000 after acquiring an additional 1,189 shares during the period. Strategic Wealth Investment Group LLC acquired a new position in Avantor during the 2nd quarter valued at about $32,000. Private Trust Co. NA grew its position in Avantor by 46.2% in the 4th quarter. Private Trust Co. NA now owns 2,769 shares of the company’s stock worth $32,000 after purchasing an additional 875 shares during the last quarter. Osaic Holdings Inc. grew its position in Avantor by 60.9% in the 2nd quarter. Osaic Holdings Inc. now owns 2,810 shares of the company’s stock worth $38,000 after purchasing an additional 1,064 shares during the last quarter. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Avantor in the fourth quarter valued at approximately $32,000. Institutional investors own 95.08% of the company’s stock.

Analyst Ratings Changes

AVTR has been the subject of several recent research reports. TD Cowen reiterated a “hold” rating on shares of Avantor in a research note on Thursday, February 12th. Evercore set a $10.00 price objective on shares of Avantor in a research report on Wednesday, February 11th. UBS Group reiterated a “neutral” rating and set a $10.50 price objective on shares of Avantor in a research note on Thursday, February 12th. Wells Fargo & Company cut their target price on shares of Avantor from $16.00 to $14.00 and set an “overweight” rating on the stock in a report on Friday, February 13th. Finally, Zacks Research upgraded Avantor from a “strong sell” rating to a “hold” rating in a research note on Thursday, April 30th. Three research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $11.39.

About Avantor

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.